Pharma Update

Roche Commitment to innovation After reallocating resources to R&D, focus is now on 'R&D Excellence' HY Roche Pharma R&D investment allocation (2018-2023, % of OPEX, CHF bn) R&D investment and profitability1 Recently approved NME share of NPV (2022, USD bn) NMEs Average R&D as '17-'221 % of revenue 2 margin '223 EBITDA 8.7 8.3 Peer 1 77 156 233 13% 55% 7.7 Peer 2 75 62 138 8 27% 34% 33% 36% 2.9bn Roche 74 141 215 10 24%* 38% 3.0bn 43% Others Peer 3 55 53 166 219 7 13% 33% 3.3bn Peer 4 52 128 180 14 18% 38% Peer 5 47 245 292 5 22% 33% Peer 6 44 120 165 18% 33% 57% 64% 5.4bn 67% 5.8bn Peer 7 34 126 161 9 17% 36% R&D 4.4bn Peer 8 26 133 159 5 23% 45% Peer 9 14 229 243 8 17% 44% Peer 10 11 235 245 11 23% 41% 2018 2022 2023 NMES '17-22 All other drugs 1 Evaluate Pharma, 2017-H1 2022 data; 2 Company financial reports 2018-2022; 3 Bloomberg; *Roche Pharma only 21

View entire presentation